Compare Summit Therapeutics Inc (SMMT) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Growth Index Fund ETF — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Vanguard Growth Index Fund ETF trades at $91.97 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 28.1× Summit Therapeutics Inc's market cap, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| SMMT | VUG | |
|---|---|---|
Market Cap | $13.71B | $384.60B |
Volume | 6,173,057 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $26.38 | $92.64 |
52-Week Low | $12.43 | $70.00 |
Typical Hold Time | 16 Days | 47 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported no revenue in 2025 and a net loss of $1.08 billion, but recent news of a $2 billion strategic investment from AstraZeneca and clinical collaborations has driven significant positive sentiment. Analyst consensus is strongly bullish with a $29.33 price target, reflecting optimism around its cancer drug pipeline.
The outlook hinges on successful clinical trials for ivonescimab, with potential upside from partnership milestones. Key risks include high cash burn, reliance on pipeline success, and competitive pressures. Investors should weigh the speculative nature of biotech investing against the substantial institutional backing and analyst confidence.
VUG trades at $91.31, down 1.2% on the day, with a bullish technical signal supported by moving averages. The ETF maintains strong long-term performance with historical annual returns around 11-12% since inception. Recent news highlights VUG's concentration in mega-cap technology stocks like Nvidia, Apple, and Microsoft, which comprise over 36% of holdings. The fund's low 0.03% expense ratio appeals to cost-conscious investors seeking growth exposure.
VUG offers compelling long-term growth potential for investors with multi-decade horizons, though its heavy tech concentration presents both opportunity and risk. While historical performance has outpaced the broader market, current market conditions show value funds outperforming growth strategies in 2026. The ETF remains suitable for buy-and-hold investors seeking large-cap growth exposure with minimal fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
